SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: stockdoc77 who wrote (49427)1/20/2019 8:08:25 PM
From: li3511  Read Replies (1) of 63276
 
> over the foot-dragging and dissembling when it came to Vioxx?

OT

This is not my understanding of the situation. There was never information that Celebrex—which remained on the market—was any safer than Vioxx. Merck ran post-marketing studies that Pfizer didn’t. Merck management made the decision that the ethical thing to do was to concede the market for COX-2 inhibitors even in the absence of head-to-head data.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News